文献速递主动脉疾病

复杂及胸腹主动脉瘤开放手术中医生改良移植物应用的国家趋势

National trends in utilization of surgeon-modified grafts for complex and thoracoabdominal aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2024-02-13

该研究基于血管质量倡议(VQI)2014至2022年数据,分析5826例复杂及胸腹主动脉瘤的复杂腔内修复术,发现医生改良腔内移植物(PMEG)数量持续增长,2021年整体超过ZFEN两倍以上(567例对256例),在高手术量医生中差异更显著;作者结论认为PMEG已成为研究性器械豁免之外复杂腹主动脉及胸腹主动脉瘤的主要腔内修复方式。

要点

  • 2014至2022年VQI共5826例复杂腔内修复:ZFEN 1895例、PMEG 3241例、平行搭桥595例、平行搭桥联合ZFEN 95例
  • 2021年PMEG整体数量超过ZFEN两倍以上(567例对256例),近肾动脉修复中接近两倍
  • 最高手术量四分位医生每年PMEG中位数18例,ZFEN仅1.6例

核心结论

  • PMEG已成为研究性器械豁免之外复杂腹主动脉及胸腹主动脉瘤的主要腔内修复方式。
  • 作者认为更广泛地发表PMEG技术、结局及与定制移植物比较将使腔内主动脉手术领域和复杂动脉瘤患者获益。

研究设计与样本

  • 研究分析了血管质量倡议(VQI)2014至2022年间所有复杂及胸腹主动脉瘤的复杂腔内修复术,以考察时间趋势。
  • 研究期间共完成5826例修复:ZFEN 1895例、PMEG 3241例、平行搭桥595例、平行搭桥联合ZFEN 95例,平均纳入2.7±0.98支血管。

主要发现

  • 随时间推移,PMEG数量整体及近肾动脉动脉瘤均稳步增加,而ZFEN数量至2017年基本趋于平稳并此后保持稳定。
  • 在最近完整年度(2021年),PMEG整体数量超过ZFEN两倍以上(567例对256例),近肾动脉修复中接近两倍。
  • 在三支血管的近肾动脉动脉瘤病例中,PMEG与ZFEN使用频率相同(43%对43%),而采用四支血管移植物构型修复的近肾动脉动脉瘤比例从2014年20%增至2021年29%(P < .001)。
  • PMEG使用的差异随外科医生手术量增加而更明显:最低四分位医生每年复杂修复<2例,PMEG与ZFEN各半;最高四分位医生每年PMEG中位数18例(四分位距10-21),ZFEN仅1.6例(四分位距0.8-3.4)。
  • PMEG的医生发起研究性器械豁免试验数量从2012年1项扩展至目前8项正在招募;因这些数据未纳入VQI,PMEG的真实数量可能显著更高。

局限性

  • 医生发起的研究性器械豁免试验数据未纳入血管质量倡议(VQI),因此PMEG的真实数量可能显著更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Custom-branched/fenestrated grafts are widely available in other countries, but in the United States, they are limited to a handful of centers, with the exception of a 3-vessel juxtarenal device (ZFEN). Consequently, many surgeons have turned to alternative strategies such as physician-modified endografts (PMEGs). We therefore sought to determine how widespread the use of these grafts is. METHODS: We studied all complex endovascular repairs of complex and thoracoabdominal aortic aneurysms in the Vascular Quality Initiative from 2014 to 2022 to examine temporal trends. RESULTS: A total of 5826 repairs were performed during the study period: 1895 ZFEN, 3241 PMEG, 595 parallel grafting, and 95 where parallel grafting was used in addition to ZFEN, with a mean of 2.7 ± 0.98 vessels incorporated. Over time, the number of PMEGs steadily increased, both overall and for juxtarenal aneurysms, whereas the number of ZFENs essentially leveled off by 2017 and has remained steady ever since. In the most recent complete year (2021), PMEGs outnumbered ZFENs by over 2:1 overall (567 to 256) and nearly twofold for juxtarenal repairs. In three-vessel cases involving juxtarenal aneurysms, PMEGs were used as frequently as ZFENs (43% vs 43%), whereas the proportion of juxtarenal aneurysms repaired using a four-vessel graft configuration increased from 20% in 2014 to 29% in 2021 (P < .001). The differences in PMEG use were more pronounced as surgeon volume increased. Surgeons in the lowest quartile of volume performed <2 complex repairs annually, evenly split between PMEGs and ZFENs. However, surgeons in the highest quartile of volume performed a median of 18 (interquartile range: 10-21) PMEGs/y, but only 1.6 (interquartile range: 0.8-3.4) ZFENs/y. The number of physician-sponsored investigational device exemption trials of PMEGs has expanded from 1 in 2012 to 8 currently enrolling. As those data are not included in the Vascular Quality Initiative, the true number of PMEGs is likely substantially higher. CONCLUSIONS: PMEGs have become the dominant endovascular repair modality of complex abdominal and thoracoabdominal aortic aneurysms outside of investigational device exemptions. The field of endovascular aortic surgery and patients with complex aneurysms would benefit from broader publication of PMEG techniques, outcomes, and comparisons to custom-manufactured grafts.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. O'Donnell TFX, Dansey KD, Schermerhorn ML, et al. National trends in utilization of surgeon-modified grafts for complex and thoracoabdominal aortic aneurysms. J Vasc Surg. 2024. PMID: 38354829. doi:10.1016/j.jvs.2024.01.216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。